SINTX Technologies, Inc. (NASDAQ: SINT), a pioneer in advanced silicon nitride biomaterials and ceramics, has secured significant intellectual property milestones to support its international commercialization efforts. On November 17, 2026, the Salt Lake City-based company announced the issuance of two patents and the allowance of three patent applications across Europe, Canada, Japan, and South Korea. These developments are integral to SINTX’s strategy to expand its footprint in orthopedic devices, biomaterials, and medical textiles markets worldwide.
The newly issued patents and allowed applications enhance protection for SINTX’s proprietary SiNERGY silicon nitride technology platforms. The company aims to translate these innovations into commercial partnerships through a combination of direct medical device distribution, technology licensing, and original equipment manufacturer (OEM) collaborations with established manufacturers.
Eric K. Olson, Chairman and CEO of SINTX Technologies, emphasized the importance of intellectual property protection in the company’s growth plans. "Robust protection of our intellectual property portfolio is critical as we prepare SINTX for commercial expansion across several markets that can benefit from our silicon nitride platform," Olson stated. He added that advancing IP rights in multiple jurisdictions supports the company’s ability to convert development efforts into revenue-generating opportunities.
In Europe, the European Patent Office has allowed two applications: No. 22212616.1 and No. 22873861.3. These applications cover methods for applying silicon nitride coatings to polymer and metal implants, and manufacturing implants with engineered surface roughness and porosity, respectively. These patents complement SINTX’s implant material technologies and facilitate engagement with potential medical device partners in the region.
Japan’s Patent No. 7935430, titled "Anti-pathogenic fibrous material," represents the latest addition to SINTX’s antipathogenic fibrous material patent family. This family focuses on fibrous materials incorporating silicon nitride for use in sutures, face masks, and wound dressings. The goal is to develop medical devices with antipathogenic properties capable of inactivating pathogens upon contact. This patent supports SINTX’s commercial ambitions in functional textiles and personal protective equipment, aligning with ongoing preclinical large animal studies of silicon nitride-treated sutures and wound dressings.
In Canada, SINTX received a patent from Application No. 3,163,598, while South Korea allowed Application No. 10-2022-7029227. Both patents belong to the antifungal composite family, which combines silicon nitride with biocompatible polymers such as polymethyl methacrylate (PMMA). These composites have potential applications in dentures and dental prostheses, positioning SINTX to pursue licensing and development partnerships with dental material manufacturers.
These patent achievements coincide with SINTX’s recent completion of its additive manufacturing facility buildout and acquisition of medical-grade 3D printing systems. The company is actively engaged in discussions with potential international commercialization partners. Additionally, SINTX is advancing its SiN/PEEK composite technology through its silicon nitride additive manufacturing platform, targeting custom and patient-specific orthopedic implants. Preclinical studies involving silicon nitride-treated medical textiles are also underway.
Olson highlighted the synergy between proprietary materials, manufacturing capabilities, and geographically tailored patent protection. "We believe that combining proprietary materials, manufacturing capabilities and geographically relevant patent protection can work together to support multiple commercial relationships and diversify SINTX's future revenue opportunities," he said.
It is noted that the three allowed patent applications remain subject to completion of grant procedures in their respective jurisdictions.
Headquartered in Salt Lake City, Utah, SINTX Technologies develops, manufactures, and commercializes patented silicon nitride ceramic biomaterials and composites for medical and industrial applications. With two decades of innovation, SINTX operates under ISO 13485:2016 and AS9100D certifications. Its product portfolio includes FDA-cleared devices such as the SiNAPTIC® Foot & Ankle Osteotomy Wedge System and OEM manufacturing of spinal implants, alongside its SiNERGY™ technology platform for biocomposite and 3D printing applications.
This release contains forward-looking statements subject to risks and uncertainties, including the possibility that allowed patent applications may not result in issued patents or may have narrower claims than anticipated. The company’s ability to commercialize its technologies, obtain regulatory approvals, and secure partnerships may also affect outcomes. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date of this release.
SINTX Technologies Expands Global Patent Portfolio to Boost Silicon Nitride Commercialization in Healthcare SINTX Technologies, a leader in silicon nitride biomaterials, announced the issuance of two patents and allowance of three patent applications in key international markets. These intellectual property developments suppo... Read the full IIPLA article: https://iipla.org/news/sintx-technologies-expands-global-patent-portfolio-to-boost-silicon-nitride-commercialization-in-healthcare